Related Experiment Video
Updated: Jul 14, 2026

Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis
Arnaud D Hauer1, Gijs H M van Puijvelde, Niels Peterse
1Division of Biopharmaceutics, Leiden University, The Netherlands. A.Hauer@LACDR.leidenuniv.nl
Objective:
Vascular endothelial growth factor receptor 2 (VEGFR2)-overexpressing cells may form an interesting target for the treatment of atherosclerosis because of their involvement in processes that contribute to this disease, such as angiogenesis.
Methods And Results:
We vaccinated mice against VEGFR2 by an orally administered DNA vaccine, comprising a plasmid, encoding murine VEGFR2, carried by live attenuated Salmonella typhimurium. This vaccine induces cellular immunity against cells that overexpress VEGFR2. Vaccination of hypercholesterolemic mice against VEGFR2 resulted in a marked induction of CD8+ cytotoxic T cells specific for VEGFR2 and led to an inhibition of angiogenesis in a hindlimb ischemia model. Interestingly, VEGFR2 vaccination attenuated the progression of preexisting advanced atherosclerotic lesions in the brachiocephalic artery of apoE-/- mice. Furthermore, VEGFR2 vaccination strongly reduced the initiation of collar-induced atherosclerosis in the carotid arteries of LDLr-/- mice. In addition, denudation of the carotid artery, as a model for postinterventional lesion formation, resulted in delayed endothelial replacement and significantly increased neointima formation on VEGFR2 vaccination.
Conclusions:
These data indicate the prominent role of VEGFR2+ cells in cardiovascular diseases and show that induction of cellular immunity against atherosclerosis-associated cells by means of DNA vaccination may contribute to the development of novel therapies against atherosclerosis.
More Related Videos
Related Concept Videos
Atherosclerosis III: Management
Regulation of Angiogenesis and Blood Supply
Atherosclerosis I: Introduction
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Mechanism of Angiogenesis
Coronary Artery Disease IV: Preventive Measures
